Ferghana Partners Group Research
Advisory Approach
Ferghana Partners Group is a specialized investment banking firm founded in 1992 that focuses exclusively on the Life Sciences sector. The firm is described as a "content strong" advisory firm, meaning they combine deep industry expertise with high-quality transaction execution. Their thesis is centered on the belief that life sciences companies—from early-stage biotechnology firms to established pharmaceutical and medical device companies—benefit from advisors who understand both the scientific complexity and the commercial dynamics of their businesses. This specialized focus allows them to identify strategic opportunities that generalist bankers might overlook.
The firm operates from principal offices in New York and London, with strategic partnerships extending their reach globally. They maintain broker-dealer registrations with FINRA (Ferghana Securities, Inc., CRD# 43430) and the SEC, positioning them as a credible transaction intermediary for regulated securities transactions and M&A advisory work.
Sector Focus
Ferghana Partners Group specializes in six core Life Sciences subsectors:
Biotechnology & Biopharmaceuticals: The firm advises on acquisitions, financings, and partnering transactions for emerging and established biotech companies developing therapeutic agents. They have particular expertise in oncology, inflammatory disease, infectious disease, gene editing, and cell therapy platforms. Representative deals include advising Cephalon on the acquisition of Arana Therapeutics (a protein engineering platform company), and serving as placement agent for Mirna Therapeutics' $34.5 million Series C financing focused on microRNA oncology therapeutics.
Pharmaceuticals & OTC Drugs: Ferghana has deep experience with specialty pharmaceutical companies developing OTC and prescription medications. The firm has advised AFT Pharmaceuticals—a New Zealand-based specialty pharma company with patented OTC products including Maxigesic—on multiple partnering transactions with global partners including Actavis, Angelini, Kern Pharma, and Stada. They also advised AFT on a $42 million equity/debt financing in 2014 with Capital Royalty Partners and Milford Asset Management. The firm understands generic drug dynamics, branded OTC positioning, and the regulatory pathways for different medication classes.
Diagnostics & Molecular Testing: Ferghana has closed numerous transactions in the diagnostics space. The firm advised Ipsogen S.A. (a publicly traded French company developing PCR-based tests for blood cancers) on its sale to Qiagen in 2011—a transaction focused on expanding molecular diagnostics and personalized healthcare portfolios. They also advised Signature Diagnostics on its sale to Roche Diagnostics Deutschland in 2015, where the transaction centered on translational research, genomics, and next-generation sequencing (NGS) capabilities for cancer detection.
Medical Devices: The firm advises on complex cross-border medical device transactions. They represented Pulsion Medical Systems (a specialty monitoring solutions provider for critically ill patients) in its 2014 sale to the Getinge Group of Sweden, focusing on cardiac monitoring, hemodynamic measurement, and critical care device expansion.
Specialty Chemicals: Ferghana advises companies developing chemicals and materials for pharmaceutical and medical applications, including pharmaceutical excipients, specialty coatings, and industrial chemicals used in drug manufacturing and medical device production.
Corporate Partnering: The firm is recognized as a pioneer and leader in corporate partnering transactions, facilitating strategic relationships between innovative biotech companies and larger pharmaceutical firms. This includes license agreements, co-development arrangements, marketing rights transactions, and joint ventures. The firm has advised companies like VitaPath Genetics on partnering their spina bifida risk assessment assay with Alere, resulting in global distribution across 42+ countries.
Deal Track Record
Ferghana has completed transactions across all four service categories (acquisitions, divestitures, financings, and partnering) and has specific expertise in:
Acquisitions: Advised Cephalon on the acquisition of Arana Therapeutics to advance inflammatory disease and oncology pipeline development (2009). The transaction catalyzed Cephalon's entrance into the biologics space with established protein engineering platform.
Divestitures/Asset Sales: Advised Ipsogen S.A. on sale to Qiagen (2011) for molecular diagnostics expansion. Advised Signature Diagnostics on sale to Roche Diagnostics Deutschland (2015). Advised Pulsion Medical Systems on sale to Getinge Group (2014) for critical care device expansion.
Financing Transactions: Served as sole placement agent for Mirna Therapeutics' $34.5 million Series C financing (2012)—one of the largest ever for a Texas biotechnology company. Advised AFT Pharmaceuticals on $42 million equity/debt financing with Capital Royalty Partners and Milford Asset Management (2014), enabling commercial expansion into 42 countries. Served as advisor to Crescendo Bioscience on its $28 million Series D financing (2013) for commercialization of Vectra DA, a blood test for rheumatoid arthritis assessment. Served as placement agent for Daktari on $15.5 million financing round (2015). Advised EntreMed on registered direct offerings and licensing transactions.
Corporate Partnering: Advised AFT Pharmaceuticals on multiple partnering transactions including deals with Actavis, Angelini, Kern Pharma, and Stada for global expansion of Maxigesic®, expanding to 42+ countries. Advised VitaPath Genetics on partnering spina bifida risk assessment assay with Alere (2011). Advised numerous other companies on license agreements and co-development arrangements.
Based on the breadth of their transaction list (50+ transactions visible on their website), Ferghana has completed well over 100 transactions over their 30+ year history, with particular depth in the biotechnology, pharmaceutical, and diagnostics sectors.
Transactional Expertise
Ferghana's strength lies in handling complex, multi-jurisdictional transactions. They lead teams of professional advisors including lawyers, accountants, tax advisors, and patent attorneys through intricate deals. Their transactional approach includes:
For Acquisitions: They identify suitable targets based on client strategic objectives, conduct market analysis, manage due diligence, negotiate deal structure and key terms, and assist with final documentation. They create and execute strategic acquisition transactions for growth or to maximize shareholder value.
For Divestitures: Ferghana deploys a rigorous, tightly controlled divestment process. They prepare information memoranda, create comprehensive offeree lists identifying all possible local, regional, and multinational acquirers, survey buyer interest discreetly before revealing the seller's identity, manage the due diligence process with sophisticated buyer management, conduct rounds of bidding, and lead final negotiations. They emphasize auction sales to maximize seller returns.
For Financing: They identify potential investors or partners, prepare pitch materials, arrange management presentations, coordinate due diligence, and assist with documentation. They serve as placement agents for equity offerings and debt financings.
For Corporate Partnering: They identify aligned strategic partners, prepare non-confidential information packages, conduct follow-up meetings, facilitate confidential material exchanges, manage counterparty due diligence, and negotiate final terms.
Process & Fee Structure
Ferghana operates on engagement basis, with specific terms negotiated per transaction. Their preference is for exclusive mandates, allowing them to manage comprehensive, controlled processes. Engagement fees are typically success-based with potential retainer components, though specific fee structures are not publicly disclosed. The firm emphasizes institutional-quality transaction execution and process management rather than transactional volume.
Engagement timelines vary depending on transaction complexity—auction processes typically span 6-12 months for complex divestitures, while financing transactions can close more rapidly depending on market conditions and investor availability.
Team & Expertise
Ferghana's team includes both transaction specialists and deep science/clinical experts. The transactional core includes:
William J. Kridel, Jr. - Managing Director, President, Chief Compliance Officer. Prior to founding Ferghana, Bill was a Managing Director at BZW (the merchant banking arm of Barclays Bank) with responsibility for corporate finance and M&A advisory services. He has spent 30+ years in investment banking focused on Life Sciences.
James R. Erickson - Senior Transaction Advisor. Experienced transaction specialist with deep expertise in deal execution and negotiation across life sciences sectors.
Paul Thompson - Vice President. Transaction specialist working on M&A advisory, financings, and partnering transactions.
Sandi Yurichuk - Deputy Managing Director. Responsible for multiple transaction practices and client management.
Ulrich S. Koch - Senior Transaction Advisor. Specializes in complex life sciences transactions.
Keith A. Moskowitz, Ph.D., MPM - Senior Transaction Advisor. Combines transactional expertise with scientific background (MPM = Master of Project Management).
On the science and clinical side, the firm employs MDs, PhDs, and specialists in gene editing, cell therapy, immunology, CNS disorders, diagnostics, intellectual property, healthcare policy, and medical technology. This unique structure allows the firm to conduct substantive technical due diligence and to advise on the clinical and scientific merit of transactions in addition to financial and commercial considerations.
Competitive Positioning
Ferghana differentiates from other M&A advisory firms through:
1. Specialized Life Sciences Focus: Unlike generalist banks that serve many industries, Ferghana focuses exclusively on life sciences. This allows their bankers and advisors to maintain deep, current knowledge of therapeutic areas, regulatory pathways, clinical development programs, and market dynamics specific to pharma, biotech, medical devices, and diagnostics.
2. Content-Strong Approach: The firm employs practicing MDs, PhDs in various life science disciplines, and clinical/scientific experts. This allows them to evaluate the scientific merit and clinical potential of transactions at a deep level—something few boutique M&A firms can do. When advising on a biotech acquisition, for example, they can evaluate the science and clinical potential of the acquired platform, not just the financial metrics.
3. Cross-Border Experience: With offices in New York and London, and global partnerships, Ferghana has deep experience in complex international transactions involving multiple regulatory regimes, currencies, and jurisdictions. This is particularly valuable for life sciences companies that operate globally.
4. Pioneer in Corporate Partnering: Ferghana has been a pioneer in the specialized field of corporate partnering transactions—a practice area that emerged as large pharmaceutical companies realized they could not rely entirely on internal R&D and began partnering with biotech innovators. The firm remains a recognized leader in facilitating these strategic relationships.
5. Rigorous Process Management: The firm emphasizes process control and institutional quality in execution. Their divestment process, for example, is described as "rigorous and tightly controlled" with careful buyer screening and multi-round bidding to maximize value.
Not a Fit If
Ferghana's focus is intentionally narrow, making them unsuitable for:
- Companies outside the life sciences sector (specialty chemicals used in pharma/medical are included, but broader industrial chemicals are not a primary focus)
- Transactions where scientific/clinical due diligence is unnecessary
- Clients seeking commodity M&A advisory on plain vanilla deals
- Very early-stage angel/seed companies without established development programs or IP
- Transactions below $5-10M enterprise value (though this is not explicitly stated, their positioning suggests they focus on businesses at sufficient scale)
Geographic Coverage
Primary coverage: United States and United Kingdom with principal offices in New York and London. Secondary markets and strategic partnerships extend coverage to Europe and select international locations. The firm has handled transactions across Europe (France, Germany, Netherlands, Sweden), Asia-Pacific (Australia, New Zealand), and North America.
Buyer Network & Industry Relationships
Over 30 years of operations, Ferghana has developed relationships with:
- Large pharmaceutical companies (Teva/Cephalon, Roche, Qiagen, Alere, Actavis, Angelini, Kern Pharma, Stada)
- Strategic acquirers in medical devices and diagnostics (Getinge Group)
- Private equity investors and capital providers (Capital Royalty Partners, Milford Asset Management)
- Major institutional investors in biotechnology and life sciences
- Global pharmaceutical companies and specialty chemical manufacturers
The firm's deal flow includes relationships with sophisticated buyers and extensive experience matching sellers with strategically aligned acquirers.